With the US in the midst of an opioid crisis, it has never been more critical for the pharmaceutical, biotechnology and academic fields to unite in a common goal to innovate and accelerate the discovery and development of novel non-opioid therapies to treat pain.
This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.
http://www.non-opioiddrugdevelopment.com/
September 27-28, 2018
Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
+ 1 617 455 4188
URLs:
Brochure https://go.evvnt.com/234426-0?pid=5569
Tickets https://go.evvnt.com/234426-1?pid=5569
Prices:
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0
Conference + 1 Workshop (standard rate): USD 2498.0
Conference Earlybird (Book by 15/06/18): USD 1299.0
Conference (Standard rate): USD 1999.0
Workshop: USD 499.0
Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)
Time: 8:00 am - 4:00 pm.Category: Conferences | Science, Health and Medicine
Venue details: Wyndham Boston Beacon Hill, 5 Blossom Street, Boston, 02114, United States